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Abstract
Introduction: Placenta percreta is associated with maternal morbidity and mortality. A hysterectomy is often needed to
control the bleeding in such cases. However, it has been advocated that placenta percreta be managed conservatively
to avoid massive pelvic bleeding and to preserve the patient’s fertility. Here, we present a case of placenta percreta
diagnosed by magnetic resonance imaging, and treated with systemic administration of methotrexate.
Case presentation: A 27-year-old nulliparous Japanese woman at 39 gestational weeks had an uncomplicated
vaginal delivery of a 3244-g infant. However, her placenta was not delivered, and we could not remove it manually.
Contrast-enhanced magnetic resonance imaging indicated deep myometrial invasion by placental tissue and the
whole placenta was strongly enhanced. Seven days post-partum, her serum human chorionic gonadotropin level was
12,656IU/L. Our patient hoped to preserve her uterus for a future pregnancy. She therefore received 13 courses of
methotrexate (50mg/week, intravenous injection). Her serum human chorionic gonadotropin level was undetectable
97 days after the first methotrexate injection. At 117 days post-partum, she had a labor-like pain every three minutes
and delivered the placenta. Our patient regained normal menses and at follow-up remained in good health.
Two years later, she delivered a healthy daughter.
Conclusion: We should try to detect placenta percreta in high-risk patients by any means. For low-risk patients, we
should give a diagnosis swiftly and control any intrauterine infection and massive bleeding.
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Introduction
Placenta percreta, where the chorionic villi invade the
myometrium, represents a major cause of obstetric
hemorrhage and is associated with maternal morbidity
and mortality. A hysterectomy is often needed to control
the bleeding in such cases [1]. Even if the bleeding can
be controlled, a hysterectomy is often chosen to prevent
profuse bleeding and infection during the infant-rearing
period. However, it has been advocated that placenta
percreta should be managed conservatively to avoid
massive pelvic bleeding and preserve the patient’s fertility.
Methotrexate (MTX) has been suggested as a possible
treatment for placenta percreta to avoid hysterectomy. For
such patients, it is also important to diagnose the condi-
tion swiftly and not to miss any patients at high risk.
Contrast-enhanced magnetic resonance imaging (MRI)
technology offers a valuable tool for an early diagnosis and
assessment of the treatment outcomes [2]. There has
been a paradigm shift in terms of treatment to more
conservative methods of management, involving uterine
conservation and leaving the placenta in situ with adju-
vant treatment of MTX in some cases or simply awaiting
spontaneous resorption of the placenta. Here, we present
a case of placenta percreta diagnosed by MRI, and treated
with systemic administration of MTX.
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Case presentation
Our patient was a 27-year-old Japanese woman, gravida
1 para 0 (G1P0010). Her obstetric history was not
significant except for a spontaneous abortion requiring
curettage 10 years previously. There was no history of
any other pelvic or abdominal surgical intervention.
She was admitted to our hospital with premature rup-
ture of the membranes and had undergone induction of
labor at 39 gestational weeks. Two days later, she had an
uncomplicated vaginal delivery of a 3244-g male infant
with a good Apgar score. However, her placenta was not
delivered. We tried manual removal of the placenta, but
felt resistance during traction of the umbilical cord.
Subsequent Doppler ultrasonography (US) examinations
showed a progressive vascular flow to the placental mass
in her uterus. We suspected placenta accreta, so we left
the whole placenta in her uterus. Fortunately, postpar-
tum bleeding was not severe and the total amount of
bleeding was 850mL, even though the umbilical cord
was torn during delivery.
We cared for the bleeding and possible infections. At
7 days post-partum, her serum human chorionic go-
nadotropin (hCG) level was 12,656IU/L. Gadolinium-
enhanced MRI also indicated deep myometrial invasion
by placental tissues, and the whole placenta was strongly
enhanced (Fig. 1a). A general physical examination re-
vealed no abnormalities. Her medical and gynecological
histories were unremarkable.
Our patient hoped to preserve her uterus for a future
pregnancy so we decided to administer 50mg MTX by
intravenous injection after obtaining informed consent
relevant to surgical and other treatment strategies.
Hematological, hepatic, and renal functions were evalu-
ated and found to be normal before the MTX injections.
Our patient experienced no untoward effects following
MTX administration, and her vaginal bleeding dimin-
ished gradually over four weeks. To avoid intrauterine
manipulation with surgical equipment and subsequent
infection (that is, diagnostic hysteroscopy), follow-up
MRI using an identical technique was performed every
four weeks to assess the treatment response. MTX ther-
apy (50mg/week) was administered 13 times. During the
course of this therapy, our patient had an intrauterine
infection and took three separate course of antibiotics.
Complete resolution of the uterine lesion was confirmed
by MRI scans (Fig. 1b). Her serum hCG level was un-
detectable (<5IU/L) 97 days after the first MTX injection
(Fig. 2). At 117 days post-partum, she had a labor-like
pain every three minutes and delivered the remnant of
the placenta with a little bleeding. The vestigial mass
weighed 80g (10×6×4cm) and histopathology indicated
placental tissue with necrosis. Her menses resumed 181
days after the first MTX injection, and a follow-up hys-
teroscopy showed no abnormal findings (Fig. 3).
Two years later, our patient (G2P1011) became preg-
nant spontaneously. We did not detect any placental la-
cunae or clear spaces on transabdominal US, nor did we
see any depletion of decidua in her uterus on MRI. She
underwent an uncomplicated vaginal delivery of a 3304-g
female infant with a good Apgar score. Postpartum bleed-
ing was not active and the total bleeding was 910mL. We
did not find any thinning of the posterior uterine muscu-
lar layer on transabdominal US, and there was no bleeding
with the dislodging of the placenta. The placenta had
histopathological features of marginal infarction and
chorioamnionitis stage 2 by the Blanc category. Two
independent pathologists did not note any deficiency
in the decidua.
Fig. 1 a Magnetic resonance imaging scan taken 7 days post-partum. Myometrial invasion by placental tissue is shown and the whole placenta
(13.4×11.6×8.6cm) was strongly enhanced. b After 13 courses of methotrexate therapy, placental tissue was reduced and none of the placenta
(7.0×6.8×6.6cm) was enhanced
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Discussion
This case illustrates a successful nonsurgical management
strategy for placenta percreta utilizing MTX, which
resulted in near-complete placental atrophy, as dem-
onstrated by a comparison of pre-treatment and post-
treatment MRI scans using gadolinium contrast. In
this case, gray-scale US and Doppler imaging were
effective for the detection of placental blood flow.
Abnormal placental adherence is believed to result
from pathological absence of the normally intervening
uterine decidua basalis and Nitabuch’s fibrinoid layer [3, 4].
Superficial invasion of the basalis layer is termed placenta
accreta (approximately 75% of cases); deeper invasion of
the myometrium is termed placenta increta (approximately
15% of cases); and even deeper invasion involving the ser-
osa or adjacent pelvic organs is termed placenta percreta
[5]. This abnormal adherence of the placenta to the uterus
can result in catastrophic intrapartum hemorrhage at the
time of placental delivery, often necessitating emergency
hysterectomy. The prevalence of placenta accreta has in-
creased more than tenfold in the past 30 years to approxi-
mately 1 in 2500 deliveries in the USA [6]. This increase
appears to relate to the increasing incidence of uterine
surgery, which results in a decidual defect that allows
abnormal placental ingrowth [7]. However, our patient
did not have this risk factor. It is also possible that pla-
centa percreta is associated with an abnormal position of
implantation in early pregnancy, for example, cornual and
angular pregnancies [8].
Placenta percreta is associated with considerable ma-
ternal morbidity and mortality. Indeed, most cases of
placenta percreta require a hysterectomy to achieve ad-
equate hemostasis [9]. Although a hysterectomy remains
the definitive therapy for placenta increta, some women
(such as in our case) desire conservation of the uterus to
ensure future fertility. For this reason, less-extreme
surgical approaches, including wedge resection of the af-
fected myometrium, have been proposed as a method of
permitting subsequent pregnancy. MTX is a potent anti-
metabolite, with mechanisms of action that include
Fig. 2 Serum human chorionic gonadotropin (HCG) levels were attenuated exponentially by methotrexate (MTX) treatment. Our patient had an
intrauterine infection, and took three courses of antibiotics. CLDM clindamycin, CPFN-PI cefcapene pivoxil, CPFX ciprofloxacin, CTM cefotiam,
FMOX flomoxef, MRI magnetic resonance imaging, PIPC piperacillin, SBTPC sultamicillin
Fig. 3 Hysteroscopy image by transvaginal ultrasonography showing
a small defect in the endometrium of the posterial wall measuring 8
mm. Another region of the endometrium was defect-free
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inhibition of trophoblast cells, reduction of placental
neovascularization, and attenuation of placental growth
factors [10]. In this case, MTX was effective in reducing
the blood flow in her placenta diagnosed by MRI and
US. Placenta previa and prior intrauterine manipulation
have been identified as significant synergistic factors for
the development of placenta accreta or percreta, with
rates as high as 50–67% in patients with a combination
of more than two prior Cesarean deliveries and a pla-
centa previa [11]. However, our patient did not have a
history of prior Cesarean delivery.
MRI and US are effective diagnostic tools. The overall
sensitivity and specificity of US for the diagnosis of
placenta accreta have been reported to be 77–93% and
71–96%, respectively [11]. The US features of placenta
accreta include loss of the normal retroplacental clear
space, anomalies of the bladder–myometrium interface,
prominent placental lacunae, and increased vascularity
at the interface of the uterus and bladder [11, 12]. By
contrast, the overall sensitivity and specificity of MRI
have been reported as 80–88% and 65–100%, respectively.
MRI features considered diagnostic of placenta accreta in-
clude abnormal uterine bulging, heterogeneous placental
signal intensity on T2-weighted images, and the presence
of dark intraplacental bands associated with lacunae on
such images [11, 12]. In our case, MRI in puerperium
showed the absence of dark intraplacental bands.
Our patient had risk factors for placental abnormality,
including a previous abortion, and dilatation and curet-
tage. However, if dilatation and curettage become a risk
of placenta accreta, she may have a repeat placenta
accreta. Previous placenta previa, submucosal fibroids,
prior Cesarean delivery, and multiparity are other recog-
nized risk factors for placenta increta and percreta. Re-
cent studies have shown that patients with placenta
accreta or percreta have high serum alpha-fetoprotein
and serum hCG levels.
It took 117 days from the initial delivery for our pa-
tient to achieve a satisfactory therapeutic response to
MTX, shown by her declining serum hCG levels and
confirmed by contrast-enhanced MRI. This successful
response obviated the need for diagnostic hysteroscopy
and possible hysterectomy to remove the residual placenta.
Placental invasion of the myometrium may be difficult
to discern using routine US. Accordingly, use of contrast-
enhanced MRI to confirm any abnormal placentation
warrants consideration in such clinical settings [13].
Conclusions
We should try to detect placenta accreta and percreta in
high-risk cases using US and MRI. For low-risk cases,
we should give a diagnosis swiftly and control any intra-
uterine infection and massive bleeding. Early diagnosis is
important so that the patient can be prepared and
adequately counselled with regard to the treatment options
and their possible consequences. Fever may also represent
an inflammatory response to tissue necrosis in the absence
of any infectious source. Infectious morbidity can
be reduced by use of prophylactic broad-spectrum anti-
biotic therapy [14] and the patient in our case had a
successful subsequent live delivery after placenta
percreta.
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